Rev. Soc. Esp. Dolor. 2022; 29(13): 10-13 / DOI: 10.20986/resed.2022.4024/2022
Juan Fernando García, Jesús de Santiago
RESUMEN
El cannabis medicinal ha sido promovido por los medios de comunicación y por la opinión pública en general. La planta del cannabis y los medicamentos a base de cannabis (CbM) han pasado por alto los estudios tradicionales basados en la evidencia, y han sido legalizados en muchos países sin pasar por el camino habitual de aprobación de los medicamentos. La comunidad médica debe conocer la evidencia actual al respecto para poder asesorar de manera competente a los pacientes. Esta revisión explicará brevemente la situación actual de la evidencia, de los obstáculos encontrados y de los posicionamientos de las respectivas sociedades del dolor respecto a la utilización del cannabis medicinal para el tratamiento del dolor.
ABSTRACT
Medical cannabis has been promoted by the media and by public opinion. The cannabis herb and cannabis-based medicines have bypassed traditional evidence-based studies, and have been legalized in many countries without going through the usual path of drug approval. The medical community must be aware of the current evidence in this regard in order to appropriately advise patients. This review will explain the current status of the evidence, the obstacles encountered to obtain evidence, and the positions of the respective pain societies regarding the use of medicinal cannabis for the treatment of pain.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Torralba A, Miquel A, Darba J. Situación actual del dolor crónico en España: iniciativa "Pain Proposal". Rev Soc Esp Dolor. 2014;21(1):16-22. DOI: 10.4321/S1134-80462014000100003.
2. Rodriguez MJ, García AJ. Costes del dolor neuropático según etiología en las Unidades del Dolor en España. Rev Soc Esp Dolor. 2007;6:404-15.
3. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-73.
4. Fitzcharles MA, Eisenberg E. Medical cannabis: a forward vision for the clinician. Eur J Pain. 2018;22(3):485-91.
5. Fitzcharles MA, Shir Y, Häuser W. Medical cannabis: strengthening evidence in the face of hype and public pressure. CMAJ. 2019;191(33):E907-8.
6. Teede R-D, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease: the IASP clas- sification of chronic pain for the international classification of diseases [ICD-11]. Pain. 2019;160(1):19-27.
7. Lynch mE, Campbell F. Cannabinoids for treatment of chronic non cancer pain. a systematic review of randomized trials. Br J Clin Pharmacol. 2011 ;72(5):735-44.
8. Chang Y, Zhu M, Vannabouathong C, Mundi R, Chou RS, Bhandari M. Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations. Pain Res Manag. 2021;2021:8857948.
9. Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl 1):S45-S66.
10. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182.
11. Mu A, Weinberg E, Moulin DE, Clarke H. Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement. Can Fam Physician. 2017;63(11):844-52.
12. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456-73.
13. Sainsbury B, Bloxham J, Pour MH, Padilla M, Enciso R. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis. J Dent Anesth Pain Med. 2021;21(6):479-506.
14. Noori A, Miroshnychenko A, Shergill Y, Ashoorion V, Rehman Y, Couban RJ, et al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. 2021;11(7):e047717.
15. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-35.
16. Häuser W, Finn DP, Kalso E, Krcevski-Skvarc N, Kress HG, Morlion B, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547-64.
17. Petzke F, Karst M, Gastmeier K, Radbruch L, Steffen E, Häuser W. Ad-hoc-Kommission der Deutschen Schmerzgesellschaft “Cannabis in der Medizin.” Position paper on medical cannabis and cannabis-based medicines in pain medicine [in German]. Schmerz. 2019;33(5):449-65.
18. National Institute for Health and Care Excellence Neuropathic pain in adults: pharmacological management in non-specialist settings. London: National Institute for Health and Care Excellence (UK). 2020.
19. Moisset X, Bouhassira D, Avez Couturier J, Alchaar H, Conradi S, Delmotte MH, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations. Rev Neurol (Paris). 2020;176(5):325-52.
20. Haroutounian S, Arendt-Nielsen L, Belton J, Blyth FM, Degenhardt L, Di Forti M, et al. International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(Suppl. 1):S117-24.
21. Eisenberg E, Morlion B, Brill S, Häuser W. Medicinal cannabis for chronic pain: The bermuda triangle of low-quality studies, countless meta-analyses and conflicting recommendations. Eur J Pain. 2022;26(6):1183-5.
22. Wang L, Hong PJ, May C, Rehman Y, Oparin Y, Hong CJ, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021;374:n1034.
23. Chung M, Kim HK, Abdi S. Update on cannabis and cannabinoids for cancer pain. Curr Opin Anaesthesiol. 2020;33(6):825-31.
24. Baswan SM, Klosner AE, Glynn K, Rajgopal A, Malik K, Yim S, et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clin Cosmet Investig Dermatol. 2020;13:927-42.